Clinical trial
A Prospective, Open-label, Controlled, Single Center Clinical Study of the Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis
NCT05965284 is registered in ClinicalTrials.gov with Chinese SLE Treatment And Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Open-label, Controlled, Single Center Clinical Study of the Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis
- Lead sponsor
- Chinese SLE Treatment And Research Group
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- March 9, 2023
- Completion date
- December 31, 2026
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anca-associated vasculitis, maintenance therapy